Nanomaterials for endometriosis: a multimodal strategy integrating targeted delivery, immunomodulation, and physical ablation
- 1School of Medicine, Qilu Institute of Technology
- 2Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University
Abstract
Endometriosis is a chronic inflammatory condition for which existing treatments, mainly hormonal therapy and surgical intervention, remain insufficient. These approaches are often limited by high recurrence rates, significant side effects, and an inability to effectively target underlying disease mechanisms. This review outlines emerging mechanism-oriented therapeutic strategies that combine targeted drug delivery, immunomodulation, and physical ablation. Advanced delivery systems, such as Lipid nanoparticle polymeric carriers, and nanomicelles, enable selective accumulation of therapeutic agents at endometriotic lesions, improving efficacy while minimizing systemic toxicity. Immunomodulatory strategies pursue to re-establish immune balance by enhancing immune surveillance, driving macrophage polarization toward anti-inflammatory states, and suppressing pro-inflammatory signaling, often through nanocarrier-enabled localized delivery. Furthermore, physical ablation techniques including gold (Au) NPs-mediated photothermal therapy and magnetic hyperthermia offer minimally invasive approaches for precise lesion elimination while preserving adjacent healthy tissues. Collectively, integrating these strategies may advance preclinical efforts to improve disease management, patient stratification, and potentially fertility outcomes, although clinical validation is still required. Despite ongoing challenges in clinical translation, the convergence of nanotechnology, immunology and interventional therapy marks a conceptual shift away from symptom-centered management toward investigational strategies that, pending clinical validation, may confer disease-modifying potential in endometriosis.
Related
- From revascularization to multimodal integrated therapy for peripheral arterial disease: immunomodulation, metabolic correction, and tissue engineering
- Hybrid risk scores integrating polygenic and clinical variables for endometriosis prediction
- Integrating disulfidptosis patterns and machine learning identifies a novel diagnostic signature for endometriosis
- Multimodal investigation of endometriosis by using LA-ICP-MS and QCL-based infrared microscopy
- Multimodal analysis reveals asynchronous aging dynamics between endometriosis-associated ovarian cancer and endometriosis patients.
BibTeX
@article{inam2026nanomaterials,
title = {{Nanomaterials for endometriosis: a multimodal strategy integrating targeted delivery, immunomodulation, and physical ablation}},
author = {Muhammad Inam and Muhammad Hayat and Fouzia Latif and Bilal Ahmed and Abuzar Osman},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1953410},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1953410/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Nanomaterials for endometriosis: a multimodal strategy integrating targeted delivery, immunomodulation, and physical ablation
AU - Muhammad Inam
AU - Muhammad Hayat
AU - Fouzia Latif
AU - Bilal Ahmed
AU - Abuzar Osman
PY - 2026
DA - 2026/10/26
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1953410
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1953410/full
AB - Endometriosis is a chronic inflammatory condition for which existing treatments, mainly hormonal therapy and surgical intervention, remain insufficient. These approaches are often limited by high recurrence rates, significant side effects, and an inability to effectively target underlying disease mechanisms. This review outlines emerging mechanism-oriented therapeutic strategies that combine targeted drug delivery, immunomodulation, and physical ablation. Advanced delivery systems, such as Lipid nanoparticle polymeric carriers, and nanomicelles, enable selective accumulation of therapeutic agents at endometriotic lesions, improving efficacy while minimizing systemic toxicity. Immunomodulatory strategies pursue to re-establish immune balance by enhancing immune surveillance, driving macrophage polarization toward anti-inflammatory states, and suppressing pro-inflammatory signaling, often through nanocarrier-enabled localized delivery. Furthermore, physical ablation techniques including gold (Au) NPs-mediated photothermal therapy and magnetic hyperthermia offer minimally invasive approaches for precise lesion elimination while preserving adjacent healthy tissues. Collectively, integrating these strategies may advance preclinical efforts to improve disease management, patient stratification, and potentially fertility outcomes, although clinical validation is still required. Despite ongoing challenges in clinical translation, the convergence of nanotechnology, immunology and interventional therapy marks a conceptual shift away from symptom-centered management toward investigational strategies that, pending clinical validation, may confer disease-modifying potential in endometriosis.
SN - 1663-9812
ER -